Combining Biomarkers (AFP, AFP-L3, and PIVKA-II) and Image Tools for Early Detection of Hepatocellular Carcinoma
Clinical Usefulness of Combining Biomarkers (AFP, AFP-L3, and PIVKA-II) With Abdominal Sonography or Computed Tomography for Early Detection of Hepatocellular Carcinoma
Sponsor: Asan Medical Center
This NA trial investigates Hepatocellular Carcinoma and Liver Cirrhosis and is currently ongoing. Asan Medical Center leads this study, which shows 7 recorded versions since 2016 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Mar 2026 — Present [monthly]
Unknown NA
Status: Recruiting → Unknown
-
Sep 2025 — Mar 2026 [monthly]
Recruiting NA
-
Sep 2024 — Sep 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Sep 2022 — Jul 2024 [monthly]
Recruiting NA
▶ Show 2 earlier versions
-
Jan 2021 — Sep 2022 [monthly]
Recruiting NA
-
Jul 2020 — Jan 2021 [monthly]
Recruiting NA
First recorded
Jul 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Asan Medical Center
- Chung-Ang University Hosptial, Chung-Ang University College of Medicine
- Hanyang University
- Inje University
- Keimyung University Dongsan Medical Center
- Konkuk University Hospital
- Korea University
- Korea University Anam Hospital
- Korea University Ansan Hospital
- Korea University Guro Hospital
- Samsung Medical Center
- Seoul National University Hospital
- Severance Hospital
- Soonchunhyang University Hospital
- The Catholic University of Korea
For direct contact, visit the study record on ClinicalTrials.gov .